Replies to post #35897 on Cel Sci Corporation (CVM)

[GD]

If the subgroup is large and efficacy is strong enough
like a "cure", it means OS KM cures have long and diverging
tail and should drive the P value into SS, hope you are
right and this should be good results street will like to see,
and logic is it should not take so many month more to get
the clear picture, CVM already knows HLA is the biomarker
to look for and the HLA data should be in the data base, IMO.

[georgebailey]

@Light,@GD--I don't know if Patients participating in Phase 3 were tested for HLA expression prior to enrollment.
I also don't know if there was enough time to test for HLA expression between initial diagnoses and completion of SOC.
I think our best scenario(and the Patient) would entail immediate tissue samples and analysis for HLA expression pre administration of SOC.